Bioabsorbable Ureteral Stent Sales

Bioabsorbable Ureteral Stent Sales Market Outlook

The global bioabsorbable ureteral stent market is projected to reach approximately USD 700 million by 2035, growing at a compound annual growth rate (CAGR) of around 9% during the forecast period from 2025 to 2035. The growth of this market is significantly driven by the rising prevalence of urinary tract diseases and kidney stones, increasing geriatric population globally, and advancements in medical technology. Additionally, the rising preference for minimally invasive procedures and the growing awareness about the benefits of bioabsorbable materials over traditional stents further propel market growth. Furthermore, the increasing investments in healthcare infrastructure and research and development activities in the medical devices sector are also expected to contribute positively to the growth trajectory of the bioabsorbable ureteral stent market.

Growth Factor of the Market

Several factors are contributing to the growth of the bioabsorbable ureteral stent market, primarily emphasizing the advantages of bioabsorbable materials. These stents are designed to dissolve over time, reducing the need for additional surgeries and minimizing the risk of complications associated with permanent implants. The increasing incidence of conditions such as ureteral obstructions and urinary tract infections is also fueling the demand for innovative stenting solutions. Moreover, the rising awareness about the benefits associated with bioabsorbable stents, including reduced postoperative complications and shorter recovery times, is promoting their adoption among healthcare providers. Technological advancements in the materials used for manufacturing these stents, combined with the rising investment in urological health, are further enhancing market growth. Additionally, government initiatives to promote advanced healthcare solutions are adding momentum to the market expansion.

Key Highlights of the Market

• The bioabsorbable ureteral stent market is set to grow at a CAGR of 9% from 2025 to 2035.
• Rising incidence of urinary tract diseases and kidney stones is a key driver for market growth.
• Technological advancements in stent materials are enhancing the efficacy and safety of stenting procedures.
• Increased preference for minimally invasive surgical procedures is boosting demand for bioabsorbable stents.
• Growing investments in healthcare infrastructure across various regions are supporting market expansion.

By Product Type

Polymer-based Stents:

Polymer-based stents are among the most commonly utilized types of bioabsorbable ureteral stents. These stents are primarily composed of biocompatible polymers that dissolve over time, providing temporary support in the ureter without the need for surgical removal. The increasing focus on patient comfort and safety has led to a rise in the adoption of polymer-based stents, as they reduce the risk of irritation and inflammation compared to traditional metal stents. Furthermore, advancements in polymer technology have improved the mechanical properties of these stents, making them more effective in managing ureteral obstructions. The growth of this segment is also supported by ongoing research aimed at enhancing the biodegradable characteristics of these materials, making them even more appealing to healthcare providers and patients alike.

Metal-based Stents:

While metal-based stents have been traditionally used in the market, their bioabsorbable variants are gaining traction due to their unique properties. Metal-based stents provide excellent support and durability, which is crucial for patients with severe ureteral obstructions. However, the main drawback is that they require additional procedures for removal, leading to higher healthcare costs and potential complications. The introduction of bioabsorbable metal stents aims to tackle these issues by offering the structural benefits of metal while allowing for gradual dissolution within the body. As more clinical studies highlight the safety and efficacy of these stents, their acceptance among urologists and patients is expected to rise, driving the segment's growth in the bioabsorbable ureteral stent market.

Composite Stents:

Composite stents, which combine various materials such as polymers and metals, are emerging as a versatile option within the bioabsorbable ureteral stent market. These stents leverage the advantages of both materials, providing the mechanical strength of metals along with the biocompatibility of polymers. This unique combination allows for better performance in managing ureteral obstructions and minimizing postoperative complications. As research into composite materials continues to advance, the properties of these stents are being optimized to enhance their biodegradability and effectiveness. The growing preference for composite stents among urologists due to their improved performance is expected to significantly contribute to the segment's growth in the coming years.

Others:

The "Others" segment encompasses various innovative stenting solutions that do not fit neatly into the predefined categories. This includes experimental designs and emerging technologies focused on enhancing the urinary tract health. Various research and development initiatives are underway to explore new materials and designs aimed at improving the efficacy of ureteral stents. This segment is characterized by its flexibility and adaptability, making it a potential area for growth as manufacturers look to meet the evolving demands of healthcare providers and patients. With ongoing advancements in materials science and engineering, the "Others" segment is expected to experience substantial growth as more innovative solutions come to market.

By Application

Hospitals:

Hospitals are a key application segment for bioabsorbable ureteral stents, accounting for a substantial portion of their demand. This can be attributed to the comprehensive care provided within hospital settings and the presence of experienced medical professionals trained to handle complex urological procedures. Hospitals are equipped with advanced diagnostic and surgical technologies, making them capable of implementing bioabsorbable stenting solutions effectively. Moreover, the rising rates of hospital admissions for urinary tract conditions, alongside the trend of adopting advanced medical technologies, are further driving the growth of this segment. The focus on minimizing postoperative complications and enhancing patient recovery times also aligns with the use of bioabsorbable stents, solidifying their application in hospitals.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) play a crucial role in the bioabsorbable ureteral stent market, driven by the trend toward outpatient procedures and minimally invasive surgeries. ASCs provide a cost-effective alternative to traditional hospital settings, allowing patients to undergo procedures and recover in less time. The ability to perform ureteral stenting in an outpatient setting is gaining popularity due to the convenience and lower associated costs for patients. Furthermore, advancements in surgical techniques and technologies are enabling ASCs to offer a wider range of urological services, including the insertion of bioabsorbable stents. As patient preference shifts towards outpatient care, the demand for bioabsorbable ureteral stents in ASCs is expected to rise significantly.

Specialty Clinics:

Specialty clinics, focusing on urology and related fields, are increasingly adopting bioabsorbable ureteral stents due to their expertise in managing urinary tract conditions. These clinics are often at the forefront of innovation and are more likely to adopt advanced medical devices that enhance patient outcomes. The growing prevalence of ureteral obstructions and kidney stones necessitates the use of effective stenting solutions, which specialty clinics are prepared to provide. Furthermore, the personalized care offered at specialty clinics contributes to the effective management of patients undergoing stenting procedures. As awareness about bioabsorbable stents rises, specialty clinics are likely to see an increase in patient referrals and the subsequent demand for these innovative solutions.

Others:

The "Others" segment in the application category is indicative of various healthcare settings where bioabsorbable ureteral stents can be utilized, including research institutions and telemedicine platforms. These environments are exploring new avenues for delivering healthcare services and managing urinary tract conditions. With the rapid advancement of telehealth, the integration of bioabsorbable stenting solutions into remote patient monitoring is becoming a possibility, allowing for improved patient management. Additionally, research institutions are constantly investigating the efficacy of new medical devices, including bioabsorbable stents, which can lead to advancements in their design and application. This segment is expected to grow as the landscape of healthcare evolves towards more innovative and patient-centric solutions.

By user

Men:

Men represent a significant user segment within the bioabsorbable ureteral stent market, primarily due to the higher prevalence of urinary tract conditions among male patients. Factors such as prostate enlargement, benign prostatic hyperplasia, and urolithiasis disproportionately affect men, necessitating the use of effective stenting solutions. Bioabsorbable stents offer distinct advantages for male patients, such as reduced risk of infection and inflammation, leading to better recovery outcomes. Moreover, as awareness and education regarding urinary health increase, more men are seeking treatment options that minimize the invasiveness of procedures. This growing demand for bioabsorbable stents tailored to male patients is expected to drive the segment's growth, encouraging further research and development in this area.

Women:

Women also constitute a vital user segment for bioabsorbable ureteral stents, with specific urological conditions prevalent in female patients. Conditions such as urinary incontinence, pelvic organ prolapse, and recurrent urinary tract infections necessitate the need for effective stenting solutions. The adoption of bioabsorbable stents in the female population is gaining traction as these devices minimize the risks associated with traditional stents, such as infection and irritation. Furthermore, healthcare providers are increasingly considering gender-specific factors when recommending treatment options, thereby increasing the likelihood of women opting for bioabsorbable stents. The growing recognition of women's health issues and the importance of personalized care are expected to drive significant growth in this segment.

By Material Type

Polyglycolic Acid:

Polyglycolic acid (PGA) is widely recognized in the market for bioabsorbable ureteral stents due to its favorable biocompatibility and biodegradability. PGA is known for its rapid absorption rate, which makes it particularly suitable for short-term applications where immediate support is needed in the ureter. The material's absorption properties are advantageous in reducing the risk of chronic complications associated with permanent stents, making it a preferred choice for many medical professionals. With ongoing research focused on enhancing the material's mechanical properties, the demand for PGA-based stents is expected to rise, especially in outpatient and minimally invasive surgical settings.

Polylactic Acid:

Polylactic acid (PLA) is another prominent material used in the manufacture of bioabsorbable ureteral stents. PLA offers excellent mechanical strength and compatibility with the human body, making it ideal for various medical applications. The slow degradation rate of PLA allows for prolonged support in the ureter, providing sufficient time for the underlying condition to be treated effectively. The increasing utilization of PLA-based stents is driven by their favorable performance characteristics, including reduced inflammation and improved patient comfort. As advancements in PLA formulation and processing continue, the market for PLA-based stents is anticipated to experience significant growth.

Others:

The "Others" segment for material type encompasses a range of alternative materials being explored for bioabsorbable ureteral stents, including novel polymers and composites that offer unique benefits. Research and development initiatives are underway to assess the efficacy and safety profiles of these alternative materials, which may lead to improved stent performance and patient outcomes. This segment reflects the innovation within the bioabsorbable ureteral stent market, where manufacturers are constantly seeking to enhance stent design and functionality. As more materials are validated for use in medical applications, this segment is expected to grow, providing healthcare providers with a wider array of options to meet patient needs.

By Region

The bioabsorbable ureteral stent market is witnessing diverse growth across various regions, with North America leading the charge due to the presence of advanced healthcare infrastructure and increased healthcare expenditures. The North American market is expected to grow at a CAGR of around 10% during the forecast period, driven by the high prevalence of urological diseases and the adoption of innovative medical devices. The emphasis on research and development in the United States is propelling the growth of bioabsorbable stents, as more healthcare providers are seeking advanced treatment solutions that reduce complication rates and improve patient outcomes. The North American market is projected to reach approximately USD 300 million by 2035, reflecting its dominant position in the global bioabsorbable ureteral stent landscape.

Europe stands as a significant market for bioabsorbable ureteral stents, accounting for a substantial share of the global demand. The increasing geriatric population and a corresponding rise in urinary tract conditions are contributing factors to the growth of this market. Countries such as Germany, the United Kingdom, and France are leading the European market due to their advanced healthcare systems and increased investments in urology. Additionally, the growing trend toward minimally invasive procedures within Europe is enhancing the acceptance of bioabsorbable stents among healthcare providers. The European bioabsorbable ureteral stent market is expected to exhibit a steady growth trajectory, reaching approximately USD 200 million by 2035 as awareness and adoption of these devices continue to expand.

Opportunities

The bioabsorbable ureteral stent market is poised for significant growth, driven by emerging opportunities that provide a favorable environment for innovation and product development. One of the primary opportunities lies in the expansion of healthcare access in developing regions, where the rising prevalence of urinary tract diseases is necessitating effective treatment solutions. With increasing investments in healthcare infrastructure and medical devices in regions such as Asia Pacific and Latin America, there is a growing demand for advanced stenting solutions that can significantly improve patient outcomes. Moreover, manufacturers have the opportunity to collaborate with local healthcare providers and governments to promote awareness and education regarding the benefits of bioabsorbable stents, further driving demand in these regions.

Another opportunity exists in the realm of technological advancements and innovation within the bioabsorbable ureteral stent market. Continuous research into new materials, designs, and stenting techniques is opening doors for the development of next-generation stents that offer improved performance and patient comfort. The integration of digital health technologies, such as remote monitoring and telemedicine, presents an opportunity for enhancing patient management and follow-up care in stenting procedures. As the healthcare landscape evolves towards more tailored and patient-centric solutions, the ability to leverage technology while providing effective treatment options will be critical for manufacturers aiming to maintain a competitive edge in the bioabsorbable ureteral stent market.

Threats

Despite the promising growth prospects for the bioabsorbable ureteral stent market, there are inherent threats that could impact the overall market dynamics. A primary concern is the potential for regulatory hurdles and stringent approval processes associated with medical devices, which can delay the entry of new products into the market. The scrutiny by regulatory bodies to ensure the safety and efficacy of bioabsorbable stents can pose challenges for manufacturers, particularly small and medium-sized enterprises that may lack the resources to navigate complex regulatory frameworks. Additionally, the market faces competition from alternative stenting solutions, including traditional metal stents and newer technologies, which could hinder the adoption of bioabsorbable stents among healthcare providers. As these alternative options continue to evolve, it is imperative for manufacturers to address these challenges proactively to ensure sustainable growth.

Another significant threat to the bioabsorbable ureteral stent market comes from market saturation and price competition. As more players enter the market, there is an escalating pressure to reduce prices, which can negatively impact profit margins for manufacturers. Furthermore, the proliferation of low-cost alternatives may lead to a decline in the perceived value of bioabsorbable stents, affecting healthcare providers' willingness to adopt them. In addition, potential complications associated with bioabsorbable stents, such as degradation issues and patient outcomes, may result in negative perceptions among healthcare professionals and patients alike. Addressing these concerns through continued innovation and education will be essential in countering these threats and maintaining market growth.

Competitor Outlook

• Boston Scientific Corporation
• Medtronic plc
• Terumo Corporation
• Cook Medical
• Johnson & Johnson
• Teleflex Incorporated
• UroGen Pharma Ltd.
• Axonics Modulation Technologies, Inc.
• Coloplast A/S
• Bard Medical Division
• Conmed Corporation
• Hollister Incorporated
• Smiths Medical
• Fujifilm Holdings Corporation
• Inspire Medical Systems, Inc.

The competitive landscape of the bioabsorbable ureteral stent market is characterized by the presence of several established players, as well as emerging companies striving to gain market share. Major players such as Boston Scientific and Medtronic are leading in terms of innovation, product development, and market reach. These companies have invested heavily in research and development initiatives, leading to the introduction of advanced bioabsorbable stenting solutions that cater to the needs of patients and healthcare providers. Their extensive distribution networks and established relationships with healthcare institutions position them well to capitalize on the growing demand for bioabsorbable stents. Additionally, strategic partnerships and collaborations with other healthcare organizations allow these companies to enhance their technology offerings and expand their market presence.

Emerging companies, including UroGen Pharma and Axonics Modulation Technologies, are also making strides in the bioabsorbable ureteral stent market. These companies are focusing on niche applications and innovative product designs that address specific patient needs. Their agile nature allows them to quickly adapt to market trends and capitalize on emerging opportunities. Furthermore, the growing emphasis on personalized medicine and tailored healthcare solutions is driving these companies to develop customized bioabsorbable stents that cater to individual patient profiles. As competition intensifies, the ability to differentiate through unique product offerings and superior patient outcomes will be critical for both established players and new entrants to thrive in the market.

In conclusion, the bioabsorbable ureteral stent market is poised for substantial growth, bolstered by advancements in technology, increasing patient demand, and expanding healthcare access. The competitive landscape is evolving, with a mix of established companies and innovative newcomers vying for market share. As the industry continues to evolve, collaboration among stakeholders, including manufacturers, healthcare providers, and regulatory bodies, will be essential to drive innovation and ensure that bioabsorbable stents remain a viable and effective treatment option for patients with urinary tract conditions. The focus on improving patient outcomes and addressing the challenges faced in the market will be paramount for the sustained success of the bioabsorbable ureteral stent market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Cook Medical
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Coloplast A/S
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Medtronic plc
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Smiths Medical
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Johnson & Johnson
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Conmed Corporation
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Terumo Corporation
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 UroGen Pharma Ltd.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Bard Medical Division
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Teleflex Incorporated
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Hollister Incorporated
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Boston Scientific Corporation
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Fujifilm Holdings Corporation
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Inspire Medical Systems, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Axonics Modulation Technologies, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Bioabsorbable Ureteral Stent Sales Market, By user
    • 6.1.1 Men
    • 6.1.2 Women
  • 6.2 Bioabsorbable Ureteral Stent Sales Market, By Application
    • 6.2.1 Hospitals
    • 6.2.2 Ambulatory Surgical Centers
    • 6.2.3 Specialty Clinics
    • 6.2.4 Others
  • 6.3 Bioabsorbable Ureteral Stent Sales Market, By Product Type
    • 6.3.1 Polymer-based Stents
    • 6.3.2 Metal-based Stents
    • 6.3.3 Composite Stents
    • 6.3.4 Others
  • 6.4 Bioabsorbable Ureteral Stent Sales Market, By Material Type
    • 6.4.1 Polyglycolic Acid
    • 6.4.2 Polylactic Acid
    • 6.4.3 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Bioabsorbable Ureteral Stent Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Bioabsorbable Ureteral Stent Sales market is categorized based on

By Product Type

• Polymer-based Stents
• Metal-based Stents
• Composite Stents
• Others

By Application

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

By user

• Men
• Women

By Material Type

• Polyglycolic Acid
• Polylactic Acid
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Boston Scientific Corporation
• Medtronic plc
• Terumo Corporation
• Cook Medical
• Johnson & Johnson
• Teleflex Incorporated
• UroGen Pharma Ltd.
• Axonics Modulation Technologies, Inc.
• Coloplast A/S
• Bard Medical Division
• Conmed Corporation
• Hollister Incorporated
• Smiths Medical
• Fujifilm Holdings Corporation
• Inspire Medical Systems, Inc.